论文部分内容阅读
为探讨在常规医疗条件下,应用重组组织型纤维蛋白溶酶原激活剂(rt-PA)和链激酶(SK)治疗急性心肌梗死(AMI)后出血并发症的发生率和出血类型,作者对美国32家参与同期治疗(治疗后观察96h)病人的医疗记录进行了回顾性分析.出血事件的记录包括出血部位、血红蛋白浓度的变化、血制品的应用和临床转归(永久性后遗症或死亡)等,并按规定的标准确定出血的严重程度.结果,共419名AMI病人接受rt-PA治疗,207名AMI病人接受SK治疗.在溶栓治疗开始后96h内,rt-PA组有30.5%,SK组有31.9%的病人经历了1次或多次出血[粗相对危险度(CRR)为1.04,95%的可信区间「(95%CI)为0.91—1.14,P=0.73」.在最初24h内,rt-PA组有21.5%、SK组有15.9%的病
To investigate the incidence of hemorrhagic complications and the type of bleeding after acute myocardial infarction (AMI) with recombinant tissue plasminogen activator (rt-PA) and streptokinase (SK) under conventional medical conditions, A retrospective analysis was performed on the medical records of 32 patients in the United States who participated in the concurrent treatment (96 h after treatment), including records of bleeding sites, changes in hemoglobin concentration, use of blood products and clinical outcomes (permanent sequelae or death) , And to determine the severity of bleeding according to the required standards.Results A total of 419 AMI patients received rt-PA treatment and 207 AMI patients received SK treatment.After 96 hours after the start of thrombolytic therapy, rt-PA group had 30.5% , 31.9% of patients in SK group experienced one or more bleeds [CRR of 1.04, 95% confidence interval “(95% CI 0.91-1.14, P = 0.73” In the first 24 h, there were 21.5% in the rt-PA group and 15.9% in the SK group